Viking Therapeutics, Inc.
A clinical-stage biopharmaceutical company in San Diego that develops experimental drugs for metabolic and endocrine disorders, including obesity. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being tested as both a weekly injection and a daily pill for weight loss. Founded in 2012 by Brian Lian, a former Wall Street biotech analyst, the company built its early pipeline by licensing programs from Ligand Pharmaceuticals.
Bought 4.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Aubuchon Neil WilliamChief Commercial Officer · 1 transaction | — | 4.5K | — | 4.5K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: +4.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.